These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 36037651)

  • 21. FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma.
    Wang Q; Tan W; Zhang Z; Chen Q; Xie Z; Yang L; Tang C; Zhuang H; Wang B; Jiang J; Ma X; Wang W; Hua Y; Shang C; Chen Y
    Apoptosis; 2024 Oct; 29(9-10):1529-1545. PubMed ID: 38824477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathogenic Th17 cell-mediated liver fibrosis contributes to resistance to PD-L1 antibody immunotherapy in hepatocellular carcinoma.
    Song M; Wang L; Jiang S; Liang J; Li W; Rao W; Du Q; Liu G; Meng H; Tang L; Li Z; Yang Y; Zhang L; Zhang B
    Int Immunopharmacol; 2024 Mar; 129():111601. PubMed ID: 38350354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment.
    Li H; You J; Wei Y; Zheng L; Yang J; Xu J; Li Y; Li Z; Yang X; Yi C
    Phytomedicine; 2024 Jan; 123():155189. PubMed ID: 37984124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
    Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interventing mitochondrial PD-L1 suppressed IFN-γ-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis.
    Li T; Huang HY; Qian B; Wang WH; Yuan Q; Zhang HY; He J; Ni KJ; Wang P; Zhao ZY; He JL; Fu SW; Xu L; Lin YC; Lin ZN
    Free Radic Biol Med; 2024 Feb; 212():360-374. PubMed ID: 38171407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma.
    Wang Y; Li H; Liang Q; Liu B; Mei X; Ma Y
    Tumour Biol; 2015 Mar; 36(3):1561-6. PubMed ID: 25371070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon-α Up-Regulates the Expression of PD-L1 Molecules on Immune Cells Through STAT3 and p38 Signaling.
    Bazhin AV; von Ahn K; Fritz J; Werner J; Karakhanova S
    Front Immunol; 2018; 9():2129. PubMed ID: 30356906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HBV-specific CD8 T cells present higher TNF-α expression but lower cytotoxicity in hepatocellular carcinoma.
    Zhao L; Jin Y; Yang C; Li C
    Clin Exp Immunol; 2020 Sep; 201(3):289-296. PubMed ID: 32474905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chrysin inhibits hepatocellular carcinoma progression through suppressing programmed death ligand 1 expression.
    Rong W; Wan N; Zheng X; Shi G; Jiang C; Pan K; Gao M; Yin Z; Gao ZJ; Zhang J
    Phytomedicine; 2022 Jan; 95():153867. PubMed ID: 34923234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion.
    Chen Z; Yu M; Zhang B; Jin L; Yu Q; Liu S; Zhou B; Yan J; Zhang W; Li X; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Ye Q; Li H; Guo L
    Oncoimmunology; 2024; 13(1):2376264. PubMed ID: 38988824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway.
    Ji HF; Yang ZQ; Han JJ; Li HF; Jin ZQ; Chen WQ; Chen FH; Gong MC
    Chin J Integr Med; 2024 Apr; 30(4):339-347. PubMed ID: 37943489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis.
    Chen J; Sun S; Li H; Cai X; Wan C
    Front Immunol; 2024; 15():1373321. PubMed ID: 38596684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Irradiation Mediates
    Cheng CC; Chang YF; Ho AS; Sie ZL; Chang JS; Peng CL; Chang CC
    Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DDR2/STAT3 Positive Feedback Loop Mediates the Immunosuppressive Microenvironment by Upregulating PD-L1 and Recruiting MDSCs in Oxaliplatin-Resistant HCC.
    Liu W; Zhang F; Quan B; Yao F; Chen R; Ren Z; Dong L; Yin X
    Cell Mol Gastroenterol Hepatol; 2024; 18(4):101377. PubMed ID: 38969205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
    Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
    Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X
    Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurons upregulate PD-L1 via IFN/STAT1/IRF1 to alleviate damage by CD8
    Wang Y; Shen Y; Liang J; Wang S; Huang Y; Zhu Q; Zhang X; Yu K; Tong G; Yang C; Li Y; Wang J; Zhao Y
    J Neuroinflammation; 2024 May; 21(1):119. PubMed ID: 38715061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High expression of circulating exosomal PD-L1 contributes to immune escape of hepatocellular carcinoma and immune clearance of chronic hepatitis B.
    Lin X; Shao H; Tang Y; Wang Q; Yang Z; Wu H; Xing T
    Aging (Albany NY); 2024 Jul; 16(14):11373-11384. PubMed ID: 39028365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mesenchymal stromal cells equipped by IFNα empower T cells with potent anti-tumor immunity.
    Zhang T; Wang Y; Li Q; Lin L; Xu C; Xue Y; Hu M; Shi Y; Wang Y
    Oncogene; 2022 Mar; 41(13):1866-1881. PubMed ID: 35145233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.